Benjami Oller-Salvia
Overview
Explore the profile of Benjami Oller-Salvia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masmudi-Martin M, Oller-Salvia B, Perea M, Teixido M, Valiente M, Giralt E, et al.
Mol Pharm
. 2025 Feb;
22(3):1384-1395.
PMID: 39924896
Monoclonal antibodies (mAbs) are changing cancer treatments. However, the presence of the blood-brain barrier (BBB) and the blood-tumor barrier (BTB) limits the use of mAbs to treat brain cancer or...
2.
Prades R, Teixido M, Oller-Salvia B
Mol Pharm
. 2025 Feb;
22(3):1100-1109.
PMID: 39899901
The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence of the blood-brain barrier (BBB). This barrier naturally protects the brain and prevents therapeutics from...
3.
Lucana M, Lucchi R, Gosselet F, Diaz-Perlas C, Oller-Salvia B
RSC Chem Biol
. 2024 Jan;
5(1):7-11.
PMID: 38179197
Protein therapeutics cannot reach the brain in sufficient amounts because of their low permeability across the blood-brain barrier. Here we report a new family of bicyclic peptide shuttles, BrainBikes, capable...
4.
Lucchi R, Lucana M, Escobar-Rosales M, Diaz-Perlas C, Oller-Salvia B
N Biotechnol
. 2023 Oct;
78:76-83.
PMID: 37820830
Antibody therapeutics show great potential to treat a variety of diseases. Often, the dose that can be safely administered is limited by side effects that arise from the interaction with...
5.
Diaz-Perlas C, Escobar-Rosales M, Morgan C, Oller-Salvia B
Methods Mol Biol
. 2023 Jun;
2676:117-129.
PMID: 37277628
Phage display facilitates the evolution of peptides and proteins for affinity selection against targets, but it is mostly limited to the chemical diversity provided by the naturally encoded amino acids....
6.
Diaz-Perlas C, Oller-Salvia B
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986688
Proteins and peptides are on the rise as therapeutic agents and represent a higher percentage of approved drugs each year: 24% in 2021 vs [...].
7.
Lucana M, Arruga Y, Petrachi E, Roig A, Lucchi R, Oller-Salvia B
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959346
Peptides show high promise in the targeting and intracellular delivery of next-generation bio- and nano-therapeutics. However, the proteolytic susceptibility of peptides is one of the major limitations of their activity...
8.
Lucchi R, Bentanachs J, Oller-Salvia B
ACS Cent Sci
. 2021 Jun;
7(5):724-738.
PMID: 34079893
The high selectivity and affinity of antibody binding have made antibodies all-pervasive tools in therapy, diagnosis, and basic science. A plethora of chemogenetic approaches has been devised to make antibodies...
9.
Watson J, Aich S, Oller-Salvia B, Drabek A, Blacklow S, Chin J, et al.
J Cell Biol
. 2021 Jan;
220(2).
PMID: 33416860
Protein micropatterning allows proteins to be precisely deposited onto a substrate of choice and is now routinely used in cell biology and in vitro reconstitution. However, drawbacks of current technology...
10.
Herranz Barbero A, Rico N, Oller-Salvia B, Aldecoa-Bilbao V, Macias-Munoz L, Wijngaard R, et al.
PLoS One
. 2020 Jun;
15(6):e0233924.
PMID: 32479524
Background: Human breast milk (BM) fortification is required to feed preterm newborns with less than 32 weeks of gestation. However, addition of fortifiers increases osmolarity and osmolarity values higher than...